Redefining DME Care

MGB is an investigational nanomedicine for DME and nAMD.

Presented by Ashvattha Therapeutics at EURETINA.

Strong safety profile; no serious adverse events noted.

Improvements in visual acuity by 6.1 ETDRS letters.

Potential for at-home monthly administration.

Distinct mechanism from traditional anti-VEGF therapies.

Next steps include larger studies with active comparators.

Training for safe self-administration planned.